ERBB2 and breast carcinoma: The combination of trastuzumab and vinorelbine is an active and rationale approach in metastatic breast cancer with a manageable toxicity profile, and can be considered for patients with HER2-positive breast cancer who have already received anthracyclines and taxanes.